Total Payments
$2,944
2024 Payments
$1,807
Companies
3
Transactions
16
Payment Breakdown by Category
Travel$1,306 (44.4%)
Research$1,123 (38.2%)
Food & Beverage$514.55 (17.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $1,306 | 4 | 44.4% |
| Unspecified | $1,123 | 6 | 38.2% |
| Food and Beverage | $514.55 | 6 | 17.5% |
Payments by Type
General
$1,821
10 transactions
Research
$1,123
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | $1,807 | 9 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,123 | 6 | $0 (2023) |
| Merck Sharp & Dohme LLC | $13.83 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,807 | 9 | Alnylam Pharmaceuticals Inc. ($1,807) |
| 2023 | $1,123 | 6 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,123) |
| 2022 | $13.83 | 1 | Merck Sharp & Dohme LLC ($13.83) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $371.74 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $151.97 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $105.00 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $82.86 | General |
| 04/04/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 04/04/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $105.00 | General |
| 04/04/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $82.86 | General |
| 04/03/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $630.33 | General |
| 04/03/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $151.97 | General |
| 04/23/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $650.26 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | ||||||
| 04/23/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | Cash or cash equivalent | $306.54 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | ||||||
| 04/23/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | Cash or cash equivalent | $30.38 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | ||||||
| 04/22/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $49.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | ||||||
| 04/22/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $45.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | ||||||
| 04/21/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | Cash or cash equivalent | $42.02 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | ||||||
| 07/14/2022 | Merck Sharp & Dohme LLC | GARDASIL 9 (Biological), VAXELIS, VAXNEUVANCE | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: VACCINE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,123 | 6 |
About Andres Isla Sanchez, APRN
Andres Isla Sanchez, APRN is a Psychiatric/Mental Health healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2018. The National Provider Identifier (NPI) number assigned to this provider is 1215413844.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Andres Isla Sanchez, APRN has received a total of $2,944 in payments from pharmaceutical and medical device companies, with $1,807 received in 2024. These payments were reported across 16 transactions from 3 companies. The most common payment nature is "Travel and Lodging" ($1,306).
Ad
Practice Information
- Specialty Psychiatric/Mental Health
- Other Specialties Psychiatric/Mental Health, Psychiatric/Mental Health
- Location Miami, FL
- Active Since 07/17/2018
- Last Updated 08/12/2024
- Taxonomy Code 163WP0808X
- Entity Type Individual
- NPI Number 1215413844
Products in Payments
- GARDASIL 9 (Biological) $13.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatric/Mental Health Doctors in Miami
Katheryn Fernandez Paul, A.p.r.n, A.P.R.N
Psychiatric/Mental Health — Payments: $6,132
Psychiatric/Mental Health $6,132
Mr. Marlon Medina
Psychiatric/Mental Health — Payments: $4,163
Psychiatric/Mental Health $4,163
Marcello De Carvalho, Msn, Aprn, Pmhnp-Bc, MSN, APRN, PMHNP-BC
Psychiatric/Mental Health — Payments: $4,125
Psychiatric/Mental Health $4,125
Mr. Albert Garcia, Arnp, Pmhnp, ARNP, PMHNP
Psychiatric/Mental Health — Payments: $3,805
Psychiatric/Mental Health $3,805
Mr. Andres Vazquez Rodriguez, Aprn, APRN
Psychiatric/Mental Health — Payments: $3,573
Psychiatric/Mental Health $3,573
Mrs. Mona Toussaint-Andre
Psychiatric/Mental Health — Payments: $2,734
Psychiatric/Mental Health $2,734